Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | NR5A2 | O00482 | 1/20 | 1.00 |
| ▸ | NR5A1 | Q13285 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.88 |
| ▸ | FABP3 | P05413 | 1/20 | 0.78 |
| ▸ | RECQL | P46063 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.66 |
| ▸ | PTAFR | P25105 | 1/20 | 0.66 |
| ▸ | HTR1D | P28221 | 1/20 | 0.66 |
| ▸ | HTR2C | P28335 | 1/20 | 0.66 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.66 |
| ▸ | DRD3 | P35462 | 1/20 | 0.66 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.66 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.63 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.63 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | GMNN | O75496 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimyristoylphosphatidylcholine SCHEMBL244839 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL10498112 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| Dimyristoylphosphatidylcholine SCHEMBL37475 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL233046 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL22693933 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| Dimyristoylphosphatidylcholine SCHEMBL236969 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL231824 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL2036043 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL24563 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| Colfosceril Palmitate SCHEMBL2734250 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360200-A1 | VACCINE COMPOSITIONS AND USES THEREOF | UNIV MICHIGAN REGENTS (US) | 2025-11-27 | — | — | US | claimed |
| WO-2025080945-A1 | LIPID NANOPARTICLES | CodeBridgeBio Inc. (US) | 2025-04-17 | — | — | WO | claimed |
| EP-4531931-A1 | VACCINE COMPOSITIONS AND USES THEREOF | The Regents of The University of Michigan (US) | 2025-04-09 | — | — | EP | claimed |
| US-20240382626-A1 | IRRADIATION AMENABLE LIPOSOMAL DYE AGGREGATES AND METHODS OF SYNTHESIS AND USE THEREOF | UNIV TEXAS (US) | 2024-11-21 | — | — | US | claimed |
| WO-2024053974-A1 | COMPOSITION FOR PHOTOTHERMAL THERAPY AND PREPARATION METHOD THEREFOR | 서울대학교산학협력단 | 2024-03-14 | — | — | WO | claimed |
| WO-2023235303-A1 | VACCINE COMPOSITIONS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-12-07 | — | — | WO | claimed |
| CN-113189234-B | Laryngeal carcinoma analysis method based on ceramide, sphingomyelin and phospholipid rich in arachidonic acid acyl chain and application | 大连医科大学附属第二医院 | 2023-05-05 | — | — | CN | claimed |
| US-20220354963-A1 | EXTRACELLULAR VESICLE LINKED TO MOLECULES AND USES THEREOF | CODIAK BIOSCIENCES, INC. (US) | 2022-11-10 | — | — | US | claimed |
| US-20220287944-A1 | SILK PERSONAL CARE COMPOSITIONS | EVOLVED BY NATURE INC (US) | 2022-09-15 | — | — | US | claimed |
| US-20220218878-A1 | CONTROLLED HEAT DELIVERY COMPOSITIONS | BAMBU VAULT LLC (US) | 2022-07-14 | — | — | US | claimed |
| CN-114728078-A | Extracellular vesicles linked to molecules and uses thereof | 科迪亚克生物科学公司 | 2022-07-08 | — | — | CN | claimed |
| EP-4017537-A1 | SILK PERSONAL CARE COMPOSITIONS | Evolved by Nature, Inc. (US) | 2022-06-29 | — | — | EP | claimed |
| WO-2021035087-A1 | SILK PERSONAL CARE COMPOSITIONS | EVOLVED BY NATURE, INC. (US) | 2021-02-25 | — | — | WO | claimed |
| WO-2020243047-A1 | CONTROLLED HEAT DELIVERY COMPOSITIONS | BAMBU VAULT LLC (US) | 2020-12-03 | — | — | WO | claimed |
| US-20180236409-A1 | PERMSELECTIVE MEMBRANE AND METHOD FOR PRODUCING THE SAME | KURITA WATER INDUSTRIES LTD. (JP) | 2018-08-23 | — | — | US | claimed |
| US-20170319719-A1 | J-Aggregate Forming Nanoparticle | UNIVERSITY HEALTH NETWORK (CA) | 2017-11-09 | — | — | US | claimed |
| WO-2016186429-A1 | COMPOSITION FOR CANCER TREATMENT COMPRISING INDOCYANINE GREEN-LIPOSOME COMPOSITE | 고려대학교산학협력단 | 2016-11-24 | — | — | WO | claimed |
| US-20150359912-A1 | J-Aggregate Forming Nanoparticle | UNIVERSITY HEALTH NETWORK (CA) | 2015-12-17 | — | — | US | claimed |
| US-20150031996-A1 | SEMICONDUCTING POLYMER NANOPARTICLES AS PHOTOACOUSTIC MOLECULAR IMAGING PROBES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-01-29 | — | — | US | claimed |
| EP-4743090-A1 | LIPOSOME ENCAPSULATED APOMORPHINE | Liposome Holdings Limited (NZ) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026088039-A1 | ENCAPSULATED APOMORPHINE COMPOSITIONS | MASSEY VENTURES LIMITED (NZ) | 2026-04-30 | — | — | WO | disclosed |
| US-20260055517-A1 | MICROORGANISMS AND ARTIFICIAL ECOSYSTEMS FOR THE PRODUCTION OF PROTEIN, FOOD, AND USEFUL CO-PRODUCTS FROM C1 SUBSTRATES | KIVERDI INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260043035-A1 | NATURE-DERIVED LIPID PARTICLES FOR USE IN AGRICULTURE | INVAIO SCIENCES INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260027147-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | LONZA SALES AG (CH) | 2026-01-29 | — | — | US | disclosed |
| US-20250360200-A1 | VACCINE COMPOSITIONS AND USES THEREOF | UNIV MICHIGAN REGENTS (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4646109-A2 | NATURAL LIPID PARTICLE FORMULATIONS FOR AGRICULTURAL APPLICATIONS | Invaio Sciences, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250281420-A1 | MACROPHAGE IMMUNOTHERAPY | UNIVERSITY OF MASSACHUSETTS | 2025-09-11 | — | — | US | disclosed |
| US-20250255985-A1 | PARVOVIRUS ITR-BASED GENE DELIVERY VECTOR SYSTEM | MODEX THERAPEUTICS, INC. | 2025-08-14 | — | — | US | disclosed |
| EP-4562156-A2 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | Lonza Sales AG (CH) | 2025-06-04 | — | — | EP | disclosed |
| US-12320014-B2 | Microorganisms and artificial ecosystems for the production of protein, food, and useful co-products from C1 substrates | KIVERDI, INC. (US) | 2025-06-03 | — | — | US | disclosed |
| US-20250161481-A1 | TARGETED LNP DELIVERY | MODEX THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20250166821-A1 | METHODS FOR PREDICTION OF TREATMENT RESPONSE IN NON-ALCOHOLIC FATTY LIVER DISEASE | SAGIMET BIOSCIENCES INC. | 2025-05-22 | — | — | US | disclosed |
| WO-2025096824-A1 | TARGETED LNP DELIVERY | MODEX THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-119856057-A | Ataxin-sensitive lipid markers for monitoring ataxin replacement therapy | 拉利玛生物医药公司 | 2025-04-18 | — | — | CN | disclosed |
| WO-2025080945-A1 | LIPID NANOPARTICLES | CodeBridgeBio Inc. (US) | 2025-04-17 | — | — | WO | disclosed |
| CN-119827669-A | Use of membrane lipidosome in preparation of teenager depression diagnosis product | 上海交通大学 | 2025-04-15 | — | — | CN | disclosed |
| US-20250115904-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | LONZA SALES AG (CH) | 2025-04-10 | — | — | US | disclosed |
| EP-4531931-A1 | VACCINE COMPOSITIONS AND USES THEREOF | The Regents of The University of Michigan (US) | 2025-04-09 | — | — | EP | disclosed |
| US-20250101601-A1 | MICROORGANISMS AND ARTIFICIAL ECOSYSTEMS FOR THE PRODUCTION OF PROTEIN, FOOD, AND USEFUL CO-PRODUCTS FROM C1 SUBSTRATES | KIVERDI INC (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4522646-A2 | APOE LIPOPROTEIN SYSTEMS | Kisbee Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-4522994-A1 | FRATAXIN-SENSITIVE LIPID MARKERS FOR MONITORING FRATAXIN REPLACEMENT THERAPY | Larimar Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-119632928-A | Several liposomal cannabinoids and uses thereof | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 2025-03-18 | — | — | CN | disclosed |
| US-20250059653-A1 | MICROORGANISMS AND ARTIFICIAL ECOSYSTEMS FOR THE PRODUCTION OF PROTEIN, FOOD, AND USEFUL CO-PRODUCTS FROM C1 SUBSTRATES | KIVERDI INC (US) | 2025-02-20 | — | — | US | disclosed |
| WO-2025012723-A1 | LIPOSOME ENCAPSULATED APOMORPHINE | MACKAY SEAN MARSHALL (NZ) | 2025-01-16 | — | — | WO | disclosed |
| US-20240425992-A1 | MICROORGANISMS AND ARTIFICIAL ECOSYSTEMS FOR THE PRODUCTION OF PROTEIN, FOOD, AND USEFUL CO-PRODUCTS FROM C1 SUBSTRATES | KIVERDI INC (US) | 2024-12-26 | — | — | US | disclosed |
| EP-2971023-B1 | METHODS OF USING NATURAL AND ENGINEERED ORGANISMS TO PRODUCE SMALL MOLECULES FOR INDUSTRIAL APPLICATION | KIVERDI INC (US) | 2024-12-11 | — | — | EP | disclosed |
| EP-4470619-A2 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | Lonza Sales AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| US-20240382626-A1 | IRRADIATION AMENABLE LIPOSOMAL DYE AGGREGATES AND METHODS OF SYNTHESIS AND USE THEREOF | UNIV TEXAS (US) | 2024-11-21 | — | — | US | disclosed |
| WO-2023220657-A9 | FRATAXIN-SENSITIVE LIPID MARKERS FOR MONITORING FRATAXIN REPLACEMENT THERAPY | LARIMAR THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-20240318187-A1 | POLYRIBONUCLEOTIDES CONTAINING REDUCED URACIL CONTENT AND USES THEREOF | MODERNATX INC (US) | 2024-09-26 | — | — | US | disclosed |
| WO-2024168193-A2 | NATURAL LIPID PARTICLE FORMULATIONS FOR AGRICULTURAL APPLICATIONS | INVAIO SCIENCES, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20240269318-A1 | NANO-DELIVERY SYSTEMS COMPRISING MODIFIED LIPIDS AND USE THEREOF | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2024-08-15 | — | — | US | disclosed |
| EP-4412593-A1 | NANO-DELIVERY SYSTEMS COMPRISING MODIFIED LIPIDS AND USE THEREOF | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2024-08-14 | — | — | EP | disclosed |
| US-20240254481-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | LONZA SALES AG (CH) | 2024-08-01 | — | — | US | disclosed |
| US-20240142476-A1 | FRATAXIN-SENSITIVE LIPID MARKERS FOR MONITORING FRATAXIN REPLACEMENT THERAPY | LARIMAR THERAPEUTICS, INC. | 2024-05-02 | — | — | US | disclosed |
| US-20240108747-A1 | EXTRACELLULAR VESICLE CONJUGATES AND USES THEREOF | LONZA SALES AG (CH) | 2024-04-04 | — | — | US | disclosed |
| CN-117801968-A | Genetically engineered bacterium for over-expressing phosphorylcholine cytidine transferase gene, construction method and application thereof | 厦门大学 | 2024-04-02 | — | — | CN | disclosed |
| WO-2024053974-A1 | COMPOSITION FOR PHOTOTHERMAL THERAPY AND PREPARATION METHOD THEREFOR | 서울대학교산학협력단 | 2024-03-14 | — | — | WO | disclosed |
| US-20240084343-A1 | METHODS OF USING NATURAL AND ENGINEERED ORGANISMS TO PRODUCE SMALL MOLECULES FOR INDUSTRIAL APPLICATION | KIVERDI INC (US) | 2024-03-14 | — | — | US | disclosed |
| US-20240060191-A1 | MICROORGANISMS AND ARTIFICIAL ECOSYSTEMS FOR THE PRODUCTION OF PROTEIN, FOOD, AND USEFUL CO-PRODUCTS FROM C1 SUBSTRATES | KIVERDI INC (US) | 2024-02-22 | — | — | US | disclosed |
| US-20240050587-A1 | LIPOSOMES COMPRISING ANTI-LOX ANTIBODY | ISTITUTO ROMAGNOLO PER LO STUDIO DEI TUMORI "DINO AMADORI" - IRST S.R.L. (IT) | 2024-02-15 | — | — | US | disclosed |
| WO-2024026345-A2 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | LONZA SALES AG (CH) | 2024-02-01 | — | — | WO | disclosed |
| US-20240024422-A1 | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2024-01-25 | — | — | US | disclosed |
| US-20240000782-A1 | METHODS AND COMPOSITIONS FOR TREATING AN OPHTHALMIC CONDITION | TELIOS PHARMA, INC. (US) | 2024-01-04 | — | — | US | disclosed |
| US-20230398074-A1 | Nucleic Acid-Based Therapy of Muscular Dystrophies | ARES CAPITAL CORPORATION, AS AGENT | 2023-12-14 | — | — | US | disclosed |
| WO-2023235303-A1 | VACCINE COMPOSITIONS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-12-07 | — | — | WO | disclosed |
| WO-2023220657-A1 | FRATAXIN-SENSITIVE LIPID MARKERS FOR MONITORING FRATAXIN REPLACEMENT THERAPY | LARIMAR THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220387-A2 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023215900-A1 | MACROPHAGE IMMUNOTHERAPY | UNIVERSITY OF MASSACHUSETTS (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20230346928-A1 | MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER | ARES CAPITAL CORPORATION, AS AGENT | 2023-11-02 | — | — | US | disclosed |
| US-20230349933-A1 | METABOLIC BIOMARKERS OF INFLAMMATORY BOWEL DISEASE | INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) | 2023-11-02 | — | — | US | disclosed |
| EP-4255569-A1 | METHODS AND COMPOSITIONS FOR TREATING AN OPHTHALMIC CONDITION | Telios Pharma, Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20230270685-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE | MODERNATX, INC. (US) | 2023-08-31 | — | — | US | disclosed |
| US-11725290-B2 | Microorganisms and artificial ecosystems for the production of protein, food, and useful co-products from C1 substrates | KIVERDI, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230190653-A1 | METHOD FOR REDUCING OFF-TARGET UPTAKE OR ACCUMULATION OF AGENTS | UNIV COLORADO REGENTS (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230193274-A1 | EXTRACELLULAR VESICLES WITH STAT3-ANTISENSE OLIGONUCLEOTIDES | CODIAK BIOSCIENCES, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| EP-4186518-A1 | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF | ModernaTX, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-11660341-B2 | mRNA combination therapy for the treatment of cancer | MODERNATX, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| CN-113189234-B | Laryngeal carcinoma analysis method based on ceramide, sphingomyelin and phospholipid rich in arachidonic acid acyl chain and application | 大连医科大学附属第二医院 | 2023-05-05 | — | — | CN | disclosed |
| US-20230132093-A1 | EXTRACELLULAR VESICLE-NLRP3 ANTAGONIST | CODIAK BIOSCIENCES, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230129331-A1 | LIPOSOMAL FORMULATIONS COMPRISING AT1 RECEPTOR BLOCKERS AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-04-27 | — | — | US | disclosed |
| WO-2023058021-A1 | NANO-DELIVERY SYSTEMS COMPRISING MODIFIED LIPIDS AND USE THEREOF | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2023-04-13 | — | — | WO | disclosed |
| US-11596609-B2 | Combinations of mRNAs encoding immune modulating polypeptides and uses thereof | MODERNATX, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| EP-4137509-A1 | COMBINATIONS OF MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | ModernaTX, Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20230041964-A1 | COMBINATIONS OF MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | MODERNATX, INC. | 2023-02-09 | — | — | US | disclosed |
| US-11571463-B2 | Polynucleotides encoding interleukin-12 (IL12) and uses thereof | MODERNATX, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20230026381-A1 | COMBINATIONS OF MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2023-01-26 | — | — | US | disclosed |
| US-20230018254-A1 | EXTRACELLULAR VESICLES WITH ANTISENSE OLIGONUCLEOTIDES TARGETING KRAS | CODIAK BIOSCIENCES, INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230002764-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | CODIAK BIOSCIENCES, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| US-20220402833-A1 | Nutritional Compositions for Plants and Soils | ENVIROKURE, INCORPORATED (US) | 2022-12-22 | — | — | US | disclosed |
| US-11504337-B2 | Polynucleotides encoding methylmalonyl-CoA mutase | MODERNATX, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| US-20220362381-A1 | REMOTELY TRIGGERED THERAPY | BAMBU VAULT LLC (US) | 2022-11-17 | — | — | US | disclosed |
| US-20220354963-A1 | EXTRACELLULAR VESICLE LINKED TO MOLECULES AND USES THEREOF | CODIAK BIOSCIENCES, INC. (US) | 2022-11-10 | — | — | US | disclosed |
| US-20220347096-A1 | LIPOSOMAL CANNABINOIDS AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2022-11-03 | — | — | US | disclosed |
| EP-3458083-B1 | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF | MODERNATX INC (US) | 2022-11-02 | — | — | EP | disclosed |
| CN-115175664-A | Liposomal formulations comprising ATI receptor blockers and uses thereof | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 2022-10-11 | — | — | CN | disclosed |
| US-20220287944-A1 | SILK PERSONAL CARE COMPOSITIONS | EVOLVED BY NATURE INC (US) | 2022-09-15 | — | — | US | disclosed |
| US-20220287949-A1 | SAFE PARTICLES FOR THE INTRODUCTION OF USEFUL CHEMICAL AGENTS IN THE BODY WITH CONTROLLED ACTIVATION | BAMBU VAULT LLC (US) | 2022-09-15 | — | — | US | disclosed |
| EP-4037718-A1 | LIPOSOMES COMPRISING ANTI-LOX ANTIBODY | Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori (I.R.S.T.) S.R.L. (IT) | 2022-08-10 | — | — | EP | disclosed |
| CN-114829586-A | Extracellular vesicle-NLRP 3 antagonists | 科迪亚克生物科学公司 | 2022-07-29 | — | — | CN | disclosed |
| US-20220229065-A1 | SENSORS AND METHODS FOR RAPID MICROBIAL DETECTION | BAMBU VAULT LLC (US) | 2022-07-21 | — | — | US | disclosed |
| US-20220226253-A1 | SAFE PARTICLES FOR THE INTRODUCTION OF USEFUL CHEMICAL AGENTS IN THE BODY WITH CONTROLLED ACTIVATION | BAMBU VAULT LLC (US) | 2022-07-21 | — | — | US | disclosed |
| US-20220218878-A1 | CONTROLLED HEAT DELIVERY COMPOSITIONS | BAMBU VAULT LLC (US) | 2022-07-14 | — | — | US | disclosed |
| CN-114728078-A | Extracellular vesicles linked to molecules and uses thereof | 科迪亚克生物科学公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114729356-A | Extracellular vesicle-ASO constructs targeting STAT6 | 科迪亚克生物科学公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114729366-A | Extracellular vesicle-ASO constructs targeting CEBP/beta | 科迪亚克生物科学公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114729327-A | Extracellular vesicles with STAT3 antisense oligonucleotides | 科迪亚克生物科学公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-3458474-B1 | COMBINATIONS OF MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | MODERNATX INC (US) | 2022-07-06 | — | — | EP | disclosed |
| EP-4017537-A1 | SILK PERSONAL CARE COMPOSITIONS | Evolved by Nature, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-4013872-A1 | EXTRACELLULAR VESICLES WITH ANTISENSE OLIGONUCLEOTIDES TARGETING KRAS | Codiak BioSciences, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-4013876-A1 | EXTRACELLULAR VESICLE-NLRP3 ANTAGONIST | Codiak BioSciences, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-4013877-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | Codiak BioSciences, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-4013878-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | Codiak BioSciences, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-4013875-A1 | EXTRACELLULAR VESICLES WITH STAT3-ANTISENSE OLIGONUCLEOTIDES | Codiak BioSciences, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| CN-114641570-A | Extracellular vesicles with KRAS-targeted antisense oligonucleotides | 科迪亚克生物科学公司 | 2022-06-17 | — | — | CN | disclosed |
| US-20220177530-A1 | RECOMBINANT SILK BASED PRODUCTS AND METHODS OF PREPARING THE SAME | EVOLVED BY NATURE, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| WO-2022120015-A1 | METHODS AND COMPOSITIONS FOR TREATING AN OPHTHALMIC CONDITION | TELIOS PHARMA, INC. (US) | 2022-06-09 | — | — | WO | disclosed |
| US-11344504-B1 | Combinations of mRNAs encoding immune modulating polypeptides and uses thereof | MODERNATX, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-11311602-B2 | Polynucleotides encoding interleukin-12 (IL12) and uses thereof | MODERNATX, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11299437-B2 | Nutritional compositions for plants and soils | EnviroKure, Inc. (US) | 2022-04-12 | — | — | US | disclosed |
| US-20220040166-A1 | Methods and Compositions of Treating an Ophthalmic Condition | KARTOS THERAPEUTICS (US) | 2022-02-10 | — | — | US | disclosed |
| CN-113966348-A | Security particles with controlled activation for introducing useful chemical agents into the body | 班布沃尔特有限公司 | 2022-01-21 | — | — | CN | disclosed |
| EP-3927344-A1 | METHODS AND COMPOSITIONS OF TREATING AN OPHTHALMIC CONDITION | Kartos Therapeutics (US) | 2021-12-29 | — | — | EP | disclosed |
| EP-3927754-A1 | SAFE PARTICLES FOR THE INTRODUCTION OF USEFUL CHEMICAL AGENTS IN THE BODY WITH CONTROLLED ACTIVATION | Bambu Vault LLC (US) | 2021-12-29 | — | — | EP | disclosed |
| US-11185510-B2 | Combinations of mRNAs encoding immune modulating polypeptides and uses thereof | MODERNATX, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20210299221-A1 | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2021-09-30 | — | — | US | disclosed |
| US-11071716-B2 | Combinations of mRNAs encoding immune modulating polypeptides and uses thereof | MODERNATX, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-20210206818-A1 | MESSENGER RIBONUCLEIC ACIDS FOR THE PRODUCTION OF INTRACELLULAR BINDING POLYPEPTIDES AND METHODS OF USE THEREOF | MODERNATX, INC. | 2021-07-08 | — | — | US | disclosed |
| US-11000573-B2 | Polynucleotides encoding interleukin-12 (IL12) and uses thereof | MODERNATX, INC. (US) | 2021-05-11 | — | — | US | disclosed |
| US-20210115481-A1 | Methods of Using Natural and Engineered Organisms to Produce Small Molecules for Industrial Application | KIVERDI INC (US) | 2021-04-22 | — | — | US | disclosed |
| US-10973917-B2 | MRNA combination therapy for the treatment of cancer | MODERNATX, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| EP-3799888-A1 | LIPOSOMES COMPRISING ANTI-LOX ANTIBODY | Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori (I.R.S.T.) S.R.L. (IT) | 2021-04-07 | — | — | EP | disclosed |
| WO-2021035087-A1 | SILK PERSONAL CARE COMPOSITIONS | EVOLVED BY NATURE, INC. (US) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021030780-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | CODIAK BIOSCIENCES, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030768-A1 | EXTRACELLULAR VESICLES WITH STAT3-ANTISENSE OLIGONUCLEOTIDES | CODIAK BIOSCIENCES, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030781-A1 | EXTRACELLULAR VESICLES WITH ANTISENSE OLIGONUCLEOTIDES TARGETING KRAS | CODIAK BIOSCIENCES, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030773-A1 | EXTRACELLULAR VESICLE-NLRP3 ANTAGONIST | CODIAK BIOSCIENCES, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030776-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | CODIAK BIOSCIENCES, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| US-20210038529-A1 | COMBINATIONS OF MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2021-02-11 | — | — | US | disclosed |
| US-20200390889-A1 | REMOTELY TRIGGERED THERAPY | BAMBU VAULT LLC (US) | 2020-12-17 | — | — | US | disclosed |
| WO-2020243047-A1 | CONTROLLED HEAT DELIVERY COMPOSITIONS | BAMBU VAULT LLC (US) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020243008-A1 | SENSORS AND METHODS FOR RAPID MICROBIAL DETECTION | BAMBU VAULT LLC (US) | 2020-12-03 | — | — | WO | disclosed |
| US-20200376081-A1 | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF | MODERNATX, INC. | 2020-12-03 | — | — | US | disclosed |
| WO-2020241925-A1 | LIPID NANOPARTICLE COMPLEX CAPTURING APTIDE FUSED WITH CELL-PENETRATING MATERIAL AND USE THEREOF | 한국과학기술원 | 2020-12-03 | — | — | WO | disclosed |
| US-20200368162-A1 | Nucleic Acid-Based Therapy of Muscular Dystrophies | MODERNATX, INC. | 2020-11-26 | — | — | US | disclosed |
| US-20200367491-A1 | LIPOSOMAL FORMULATIONS AND METHODS OF USING SAME IN AGRICULTURE | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2020-11-26 | — | — | US | disclosed |
| US-10722599-B2 | Lipid assemblies and uses thereof and some pH and electrostatic modulating lipids to be used in said assemblies | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2020-07-28 | — | — | US | disclosed |
| WO-2020123656-A1 | METHODS AND COMPOSITIONS OF TREATING AN OPHTHALMIC CONDITION | KARTOS THERAPEUTICS (US) | 2020-06-18 | — | — | WO | disclosed |
| US-20200165733-A1 | Microorganisms and Artificial Ecosystems for the Production of Protein, Food, and Useful Co-Products from C1 Substrates | KIVERDI, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| US-10646549-B2 | Polynucleotides encoding interleukin-12 (IL12) and uses thereof | MODERNATX, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20200113844-A1 | COMBINATIONS OF MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | MODERNATX, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| US-20200078314-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE | MODERNATX, INC. (US) | 2020-03-12 | — | — | US | disclosed |
| US-20200054747-A1 | MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER | ARES CAPITAL CORPORATION, AS AGENT | 2020-02-20 | — | — | US | disclosed |
| US-10426738-B2 | Polynucleotides encoding methylmalonyl-CoA mutase | MODERNATX, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10406113-B2 | Combinations of mRNAs encoding immune modulating polypeptides and uses thereof | MODERNATX, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-10406112-B2 | Polynucleotides encoding methylmalonyl-CoA mutase | MODERNATX, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-10335486-B2 | MRNA combination therapy for the treatment of cancer | MODERNATX, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20190194081-A1 | Nutritional Compositions For Plants And Soils | ENVIROKURE INCORPORATED | 2019-06-27 | — | — | US | disclosed |
| US-10322090-B2 | Combinations of mRNAs encoding immune modulating polypeptides and uses thereof | MODERNATX, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-10322091-B2 | Combinations of mRNAs encoding immune modulating polypeptides and uses thereof | MODERNATX, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-20190167811-A1 | LIPID COMPOSITIONS AND THEIR USES FOR INTRATUMORAL POLYNUCLEOTIDE DELIVERY | MODERNATX, INC. | 2019-06-06 | — | — | US | disclosed |
| US-10285950-B2 | Combinations of mRNAs encoding immune modulating polypeptides and uses thereof | MODERNATX, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20190125839-A1 | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2019-05-02 | — | — | US | disclosed |
| US-20190111003-A1 | COMBINATIONS OF MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2019-04-18 | — | — | US | disclosed |
| US-20190105281-A1 | COMBINATIONS OF MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2019-04-11 | — | — | US | disclosed |
| US-20190105280-A1 | COMBINATIONS OF MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2019-04-11 | — | — | US | disclosed |
| US-20190098895-A1 | LIPOSOMAL FORMULATIONS AND METHODS OF USING SAME IN AGRICULTURE | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2019-04-04 | — | — | US | disclosed |
| EP-3442590-A2 | LIPID COMPOSITIONS AND THEIR USES FOR INTRATUMORAL POLYNUCLEOTIDE DELIVERY | Modernatx, Inc. (US) | 2019-02-20 | — | — | EP | disclosed |
| US-20190022019-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE | MODERNATX INC (US) | 2019-01-24 | — | — | US | disclosed |
| EP-3430150-A1 | MICROORGANISMS AND ARTIFICIAL ECOSYSTEMS FOR THE PRODUCTION OF PROTEIN, FOOD, AND USEFUL CO-PRODUCTS FROM C1 SUBSTRATES | Kiverdi, Inc. (US) | 2019-01-23 | — | — | EP | disclosed |
| US-10172808-B2 | Combinations of mRNAs encoding immune modulating polypeptides and uses thereof | MODERNATX, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180369374-A1 | MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER | ARES CAPITAL CORPORATION, AS AGENT | 2018-12-27 | — | — | US | disclosed |
| EP-3405579-A1 | MESSENGER RIBONUCLEIC ACIDS FOR THE PRODUCTION OF INTRACELLULAR BINDING POLYPEPTIDES AND METHODS OF USE THEREOF | Modernatx, Inc. (US) | 2018-11-28 | — | — | EP | disclosed |
| US-20180318229-A1 | COMBINATIONS OF MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2018-11-08 | — | — | US | disclosed |
| EP-3390324-A1 | FERTILIZER COMPOSITIONS FOR PLANTS AND SOILS | Envirokure Incorporated (US) | 2018-10-24 | — | — | EP | disclosed |
| EP-3390630-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE | Modernatx, Inc. (US) | 2018-10-24 | — | — | EP | disclosed |
| US-20180289838-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE | ARES CAPITAL CORPORATION, AS AGENT | 2018-10-11 | — | — | US | disclosed |
| US-20180271795-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE | ARES CAPITAL CORPORATION, AS AGENT | 2018-09-27 | — | — | US | disclosed |
| WO-2018157009-A1 | NUCLEIC ACID-BASED THERAPY OF MUSCULAR DYSTROPHIES | MODERNATX, INC. (US) | 2018-08-30 | — | — | WO | disclosed |
| EP-3142642-B1 | LIPOSOMAL MUPIROCIN | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2018-08-29 | — | — | EP | disclosed |
| US-20180236409-A1 | PERMSELECTIVE MEMBRANE AND METHOD FOR PRODUCING THE SAME | KURITA WATER INDUSTRIES LTD. (JP) | 2018-08-23 | — | — | US | disclosed |
| US-10039715-B2 | Liposomal formulation of nonglycosidic ceramides and uses thereof | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10004688-B2 | Liposomal mupirocin | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2018-06-26 | — | — | US | disclosed |
| EP-2654779-B1 | LIPOSOMAL FORMULATION OF NONGLYCOSIDIC CERAMIDES AND USES THEREOF | LUDWIG INST FOR CANCER RES LTD (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20180043036-A1 | LIPID ASSEMBLIES AND USES THEREOF AND SOME pH AND ELECTROSTATIC MODULATING LIPIDS TO BE USED IN SAID ASSEMBLIES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2018-02-15 | — | — | US | disclosed |
| WO-2017201317-A1 | POLYRIBONUCLEOTIDES CONTAINING REDUCED URACIL CONTENT AND USES THEREOF | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| US-20170319719-A1 | J-Aggregate Forming Nanoparticle | UNIVERSITY HEALTH NETWORK (CA) | 2017-11-09 | — | — | US | disclosed |
| WO-2017180917-A2 | LIPID COMPOSITIONS AND THEIR USES FOR INTRATUMORAL POLYNUCLEOTIDE DELIVERY | MODERNATX, INC. (US) | 2017-10-19 | — | — | WO | disclosed |
| WO-2017165244-A1 | MICROORGANISMS AND ARTIFICIAL ECOSYSTEMS FOR THE PRODUCTION OF PROTEIN, FOOD, AND USEFUL CO-PRODUCTS FROM C1 SUBSTRATES | KIVERDI, INC. (US) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017127750-A1 | MESSENGER RIBONUCLEIC ACIDS FOR THE PRODUCTION OF INTRACELLULAR BINDING POLYPEPTIDES AND METHODS OF USE THEREOF | MODERNATX, INC. (US) | 2017-07-27 | — | — | WO | disclosed |
| WO-2017115991-A1 | COMPOSITION CONTAINING ANTICANCER DRUG-INDOCYANINE GREEN-LIPOSOME COMPLEX FOR TREATING CANCER | 한국과학기술원 | 2017-07-06 | — | — | WO | disclosed |
| WO-2017112605-A1 | FERTILIZER COMPOSITIONS FOR PLANTS AND SOILS | ENVIROKURE, INCORPORATED (US) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017106799-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE | MODERNATX, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20170159087-A1 | Methods of Using Natural and Engineered Organisms to Produce Small Molecules for Industrial Application | KIVERDI, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170105936-A1 | LIPOSOMAL FORMULATION OF NONGLYCOSIDIC CERAMIDES AND USES THEREOF | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (US) | 2017-04-20 | — | — | US | disclosed |
| EP-3142642-A1 | LIPOSOMAL MUPIROCIN | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2017-03-22 | — | — | EP | disclosed |
| US-20170027869-A1 | LIPOSOMAL MUPIROCIN | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2017-02-02 | — | — | US | disclosed |
| US-9556462-B2 | Methods of using natural and engineered organisms to produce small molecules for industrial application | KIVERDI, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| WO-2016186429-A1 | COMPOSITION FOR CANCER TREATMENT COMPRISING INDOCYANINE GREEN-LIPOSOME COMPOSITE | 고려대학교산학협력단 | 2016-11-24 | — | — | WO | disclosed |
| US-20150359912-A1 | J-Aggregate Forming Nanoparticle | UNIVERSITY HEALTH NETWORK (CA) | 2015-12-17 | — | — | US | disclosed |
| WO-2015155773-A1 | LIPOSOMAL MUPIROCIN | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2015-10-15 | — | — | WO | disclosed |
| US-20150241456-A1 | METHODS FOR USING LIPID PARTICLES | NDSU RESEARCH FOUNDATION | 2015-08-27 | — | — | US | disclosed |
| US-20150031996-A1 | SEMICONDUCTING POLYMER NANOPARTICLES AS PHOTOACOUSTIC MOLECULAR IMAGING PROBES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-01-29 | — | — | US | disclosed |
| US-20140273112-A1 | METHODS OF USING NATURAL AND ENGINEERED ORGANISMS TO PRODUCE SMALL MOLECULES FOR INDUSTRIAL APPLICATION | KIVERDI, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140050780-A1 | LIPOSOMAL FORMULATION OF NONGLYCOSIDIC CERAMIDES AND USES THEREOF | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (US) | 2014-02-20 | — | — | US | disclosed |
| EP-2654779-A1 | LIPOSOMAL FORMULATION OF NONGLYCOSIDIC CERAMIDES AND USES THEREOF | Ludwig Institute for Cancer Research, Ltd. (US) | 2013-10-30 | — | — | EP | disclosed |
| EP-2578237-A1 | Compositions and methods for enhancing contrast in imaging | Marval Biosciences, Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20130052259-A1 | LIPOSOMES COMPRISING AMPHIPATHIC DRUGS AND METHOD FOR THEIR PREPARATION | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2013-02-28 | — | — | US | disclosed |
| WO-2012088414-A1 | LIPOSOMAL FORMULATION OF NONGLYCOSIDIC CERAMIDES AND USES THEREOF | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20120003159-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CONTRAST IN IMAGING | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-01-05 | — | — | US | disclosed |
| US-7785568-B2 | Sterically stabilized liposomes with hydrophilic polymers on surface; computed tomography | MARVAL BIOSCIENCES, INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20080131369-A1 | Sterically stabilized liposomes with hydrophilic polymers on surface; computed tomography | MARVEL THERAPEUTICS (US) | 2008-06-05 | — | — | US | disclosed |
| US-20070212303-A1 | Sterically stabilized liposomes with hydrophilic polymers on surface; computed tomography | MARVAL PHARMA, INC. | 2007-09-13 | — | — | US | disclosed |
| EP-0661049-B1 | Use of essential fatty acid compositions | UNIV LIMBURG (NL) | 1999-08-18 | — | — | EP | disclosed |
| EP-0661049-A1 | Use of essential fatty acid compositions | RIJKSUNIVERSITEIT LIMBURG (NL) | 1995-07-05 | — | — | EP | disclosed |
| EP-0661049-A1 | Use of essential fatty acid compositions | RIJKSUNIVERSITEIT LIMBURG (NL) | 1995-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132093-A1 | EXTRACELLULAR VESICLE-NLRP3 ANTAGONIST | NLRP3, MTREX, NOD1 | SMN1; SMN2 1776/4885NR5A2 1281/4885NR5A1 3029/4885 |
| US-20250161481-A1 | TARGETED LNP DELIVERY | CD4, LCP2, CD2 | SMN1; SMN2 1793/4885NR5A2 3461/4885NR5A1 4573/4885 |
| US-20200368162-A1 | Nucleic Acid-Based Therapy of Muscular Dystrophies | SMN1; SMN2, MTPN, MYOF | SMN1; SMN2 1/4885NR5A2 3675/4885NR5A1 4555/4885 |
| US-11504337-B2 | Polynucleotides encoding methylmalonyl-CoA mutase | POLM, EMG1, MCM6 | SMN1; SMN2 208/4885NR5A2 4541/4885NR5A1 3753/4885 |
| US-11344504-B1 | Combinations of mRNAs encoding immune modulating polypeptides and uses thereof | IL36G, IL23R, CD74 | SMN1; SMN2 3184/4885NR5A2 3713/4885NR5A1 2963/4885 |
| US-20180043036-A1 | LIPID ASSEMBLIES AND USES THEREOF AND SOME pH AND ELECTROSTATIC MODULATING LIPIDS TO BE USED IN SAID ASSEMBLIES | PHOSPHO1, SGMS1, SGMS2 | SMN1; SMN2 4852/4885NR5A2 4606/4885NR5A1 4369/4885 |
| US-20200390889-A1 | REMOTELY TRIGGERED THERAPY | CD47, IFNG, TLR9 | SMN1; SMN2 2935/4885NR5A2 4038/4885NR5A1 4763/4885 |
| US-20140050780-A1 | LIPOSOMAL FORMULATION OF NONGLYCOSIDIC CERAMIDES AND USES THEREOF | CERS2, CERT1, SGMS1 | SMN1; SMN2 2234/4885NR5A2 4139/4885NR5A1 3948/4885 |
| US-20250115904-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | STAT6, STAT1, STAT5B | SMN1; SMN2 542/4885NR5A2 2931/4885NR5A1 3625/4885 |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | APOB, APOL1, LDLR | SMN1; SMN2 1150/4885NR5A2 2095/4885NR5A1 3094/4885 |
| US-20200113844-A1 | COMBINATIONS OF MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | IL36G, IL23R, CD74 | SMN1; SMN2 3184/4885NR5A2 3713/4885NR5A1 2963/4885 |
| US-20260055517-A1 | MICROORGANISMS AND ARTIFICIAL ECOSYSTEMS FOR THE PRODUCTION OF PROTEIN, FOOD, AND USEFUL CO-PRODUCTS FROM C1 SUBSTRATES | PCCA, MAX, CYC1 | SMN1; SMN2 3235/4885NR5A2 3804/4885NR5A1 2126/4885 |
| US-10426738-B2 | Polynucleotides encoding methylmalonyl-CoA mutase | POLM, EMG1, MCM6 | SMN1; SMN2 208/4885NR5A2 4541/4885NR5A1 3753/4885 |
| US-20170105936-A1 | LIPOSOMAL FORMULATION OF NONGLYCOSIDIC CERAMIDES AND USES THEREOF | CERS2, CERT1, SGMS1 | SMN1; SMN2 2234/4885NR5A2 4139/4885NR5A1 3948/4885 |
| US-11571463-B2 | Polynucleotides encoding interleukin-12 (IL12) and uses thereof | IL2, IL15, RBM12 | SMN1; SMN2 289/4885NR5A2 4653/4885NR5A1 4830/4885 |
| US-20220362381-A1 | REMOTELY TRIGGERED THERAPY | CD47, HSP90AA1, HSF1 | SMN1; SMN2 1700/4885NR5A2 4151/4885NR5A1 4505/4885 |
| US-20230270685-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE | POLM, EMG1, MCM6 | SMN1; SMN2 208/4885NR5A2 4541/4885NR5A1 3753/4885 |
| US-10172808-B2 | Combinations of mRNAs encoding immune modulating polypeptides and uses thereof | IL36G, IL23R, CD74 | SMN1; SMN2 3184/4885NR5A2 3713/4885NR5A1 2963/4885 |
| US-10004688-B2 | Liposomal mupirocin | LIPA, MAN2B1, MPI | SMN1; SMN2 2591/4885NR5A2 4288/4885NR5A1 3266/4885 |
| US-10322090-B2 | Combinations of mRNAs encoding immune modulating polypeptides and uses thereof | IL36G, IL23R, CD74 | SMN1; SMN2 3184/4885NR5A2 3713/4885NR5A1 2963/4885 |
| US-20240269318-A1 | NANO-DELIVERY SYSTEMS COMPRISING MODIFIED LIPIDS AND USE THEREOF | LIPA, SGMS2, CETP | SMN1; SMN2 4545/4885NR5A2 1595/4885NR5A1 1746/4885 |
| US-20230193274-A1 | EXTRACELLULAR VESICLES WITH STAT3-ANTISENSE OLIGONUCLEOTIDES | STAT3, STAT1, STAT6 | SMN1; SMN2 887/4885NR5A2 3318/4885NR5A1 3771/4885 |
| US-20190111003-A1 | COMBINATIONS OF MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | IL36G, IL23R, CD74 | SMN1; SMN2 3184/4885NR5A2 3713/4885NR5A1 2963/4885 |
| US-20230129331-A1 | LIPOSOMAL FORMULATIONS COMPRISING AT1 RECEPTOR BLOCKERS AND USES THEREOF | AGTR1, AGTR2, ADRB1 | SMN1; SMN2 4322/4885NR5A2 987/4885NR5A1 1074/4885 |
| US-20180318229-A1 | COMBINATIONS OF MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | IL36G, IL23R, CD74 | SMN1; SMN2 3184/4885NR5A2 3713/4885NR5A1 2963/4885 |
| US-10973917-B2 | MRNA combination therapy for the treatment of cancer | CD274, PDCD1LG2, ICOSLG | SMN1; SMN2 2149/4885NR5A2 2799/4885NR5A1 3390/4885 |
| US-20260027147-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | CEBPZ, OSBP, DIS3 | SMN1; SMN2 1119/4885NR5A2 1807/4885NR5A1 1445/4885 |
| US-20190105280-A1 | COMBINATIONS OF MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | IL36G, IL23R, CD74 | SMN1; SMN2 3184/4885NR5A2 3713/4885NR5A1 2963/4885 |
| US-20250166821-A1 | METHODS FOR PREDICTION OF TREATMENT RESPONSE IN NON-ALCOHOLIC FATTY LIVER DISEASE | ACACB, ACACA, ACLY | SMN1; SMN2 3806/4885NR5A2 2080/4885NR5A1 1779/4885 |
| US-20180289838-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE | POLM, EMG1, MCM6 | SMN1; SMN2 208/4885NR5A2 4541/4885NR5A1 3753/4885 |
| US-11185510-B2 | Combinations of mRNAs encoding immune modulating polypeptides and uses thereof | IL36G, IL23R, CD74 | SMN1; SMN2 3184/4885NR5A2 3713/4885NR5A1 2963/4885 |
| US-10406113-B2 | Combinations of mRNAs encoding immune modulating polypeptides and uses thereof | IL36G, IL23R, CD74 | SMN1; SMN2 3184/4885NR5A2 3713/4885NR5A1 2963/4885 |
| US-20190167811-A1 | LIPID COMPOSITIONS AND THEIR USES FOR INTRATUMORAL POLYNUCLEOTIDE DELIVERY | RNMT, PHOSPHO1, POLM | SMN1; SMN2 927/4885NR5A2 2674/4885NR5A1 3093/4885 |
| US-11660341-B2 | mRNA combination therapy for the treatment of cancer | CD274, PDCD1LG2, ICOSLG | SMN1; SMN2 2149/4885NR5A2 2799/4885NR5A1 3390/4885 |
| US-10406112-B2 | Polynucleotides encoding methylmalonyl-CoA mutase | POLM, EMG1, MCM6 | SMN1; SMN2 208/4885NR5A2 4541/4885NR5A1 3753/4885 |
| US-20240000782-A1 | METHODS AND COMPOSITIONS FOR TREATING AN OPHTHALMIC CONDITION | BTK, SYK, LCK | SMN1; SMN2 4355/4885NR5A2 4224/4885NR5A1 3011/4885 |
| US-20240318187-A1 | POLYRIBONUCLEOTIDES CONTAINING REDUCED URACIL CONTENT AND USES THEREOF | UPF1, NUDT21, RNMT | SMN1; SMN2 556/4885NR5A2 4692/4885NR5A1 4696/4885 |
| US-11311602-B2 | Polynucleotides encoding interleukin-12 (IL12) and uses thereof | IL2, IL15, RBM12 | SMN1; SMN2 289/4885NR5A2 4653/4885NR5A1 4830/4885 |
| US-10322091-B2 | Combinations of mRNAs encoding immune modulating polypeptides and uses thereof | IL36G, IL23R, CD74 | SMN1; SMN2 3184/4885NR5A2 3713/4885NR5A1 2963/4885 |
| US-20200054747-A1 | MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER | CD274, PDCD1LG2, ICOSLG | SMN1; SMN2 2149/4885NR5A2 2799/4885NR5A1 3390/4885 |
| US-20180369374-A1 | MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER | CD274, PDCD1LG2, ICOSLG | SMN1; SMN2 2149/4885NR5A2 2799/4885NR5A1 3390/4885 |
| US-20220354963-A1 | EXTRACELLULAR VESICLE LINKED TO MOLECULES AND USES THEREOF | EXOSC5, EXOSC4, EXOSC10 | SMN1; SMN2 1847/4885NR5A2 4354/4885NR5A1 4277/4885 |
| US-10335486-B2 | MRNA combination therapy for the treatment of cancer | CD274, PDCD1LG2, ICOSLG | SMN1; SMN2 2149/4885NR5A2 2799/4885NR5A1 3390/4885 |
| US-20230018254-A1 | EXTRACELLULAR VESICLES WITH ANTISENSE OLIGONUCLEOTIDES TARGETING KRAS | KRAS, DIS3, EXOSC5 | SMN1; SMN2 625/4885NR5A2 4114/4885NR5A1 4556/4885 |
| US-20230026381-A1 | COMBINATIONS OF MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | IL36G, IL23R, CD74 | SMN1; SMN2 3184/4885NR5A2 3713/4885NR5A1 2963/4885 |
| US-20260043035-A1 | NATURE-DERIVED LIPID PARTICLES FOR USE IN AGRICULTURE | CETP, PLTP, DGAT2 | SMN1; SMN2 3088/4885NR5A2 1746/4885NR5A1 977/4885 |
| US-10722599-B2 | Lipid assemblies and uses thereof and some pH and electrostatic modulating lipids to be used in said assemblies | PHOSPHO1, SGMS1, SGMS2 | SMN1; SMN2 4852/4885NR5A2 4606/4885NR5A1 4369/4885 |
| US-10039715-B2 | Liposomal formulation of nonglycosidic ceramides and uses thereof | CERS2, CERT1, SGMS1 | SMN1; SMN2 2234/4885NR5A2 4139/4885NR5A1 3948/4885 |
| US-20210299221-A1 | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF | IL2, IL15, RBM12 | SMN1; SMN2 289/4885NR5A2 4653/4885NR5A1 4830/4885 |
| US-20230346928-A1 | MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER | CD274, PDCD1LG2, ICOSLG | SMN1; SMN2 2149/4885NR5A2 2799/4885NR5A1 3390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.